首页 > 最新文献

Journal of Drugs in Dermatology最新文献

英文 中文
Genomic Analysis Aids in the Management of Dermoscopically Atypical Pigmented Lesions. 基因组分析有助于皮肤镜下非典型色素病变的治疗。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-09-01 DOI: 10.36849/JDD.8454
Gary L Peck, Samantha R Johnson, Sarah W Matthews, Burkhard Jansen, Loren E Clarke, Rachel A Reifer, Maral Kibarian Skelsey

Background: Numerous melanoma-specific dermoscopic features have been described in invasive melanomas, while fewer features are found in melanoma in situ (MIS) and atypical nevi (ATN). Consensus regarding which features are critical for the differentiation of MIS from ATN has not been reached.

Purpose: Determine 1) whether there are dermoscopic features that differentiate early MIS from ATN, and 2) whether non-invasive assessment of genomic biomarkers (LINC00518 and PRAME) can aid in patient management.

Methods: From 2018 to 2023, 56 melanomas were evaluated for 5 clinical and 13 dermoscopic features and melanoma-associated genomic biomarkers. Two groups of ATN with positive and negative genomic biomarkers were randomly selected for comparison.

Results: All melanomas in this study expressed one or both melanoma-associated genomic markers. MIS had an average of 3.90 (range, 2-7) of the 13 dermoscopic features, while invasive melanomas had an average of 4.44 (range, 3-6). Sixteen of 40 (40%) MIS and 3 of 16 (18.8%) invasive melanomas had 3 or fewer dermoscopic features. These findings were comparable to those observed in both ATN groups. The most common dermoscopic features were absent or diminished pigment network, regression structures, and granularity. This combination of features was most helpful in identifying lesions for genomic testing.

Conclusions: Clinical and dermoscopic features alone could not differentiate MIS from ATN. Non-invasive genomic testing helped differentiate lower from higher-risk lesions and aid in clinical management decisions. Genomic testing was particularly helpful in patients with large numbers of lesions with several being considered for biopsy based on clinical and dermoscopic examination. J Drugs Dermatol. 2024;23(9):717-723. doi:10.36849/JDD.8454.

背景:在浸润性黑色素瘤中发现了许多黑色素瘤特有的皮肤镜特征,而在原位黑色素瘤(MIS)和非典型痣(ATN)中发现的特征较少。关于哪些特征是区分MIS和ATN的关键,尚未达成共识。目的:确定1)是否有皮肤镜特征可区分早期MIS和ATN;2)基因组生物标志物(LINC00518和PRAME)的非侵入性评估是否有助于患者管理:从2018年到2023年,对56例黑色素瘤的5个临床特征和13个皮肤镜特征以及黑色素瘤相关基因组生物标志物进行了评估。随机抽取基因组生物标志物阳性和阴性的两组ATN进行对比:结果:本研究中的所有黑色素瘤都表达了一种或两种黑色素瘤相关基因组标记物。在 13 个皮肤镜特征中,MIS 平均有 3.90 个特征(范围为 2-7),而侵袭性黑色素瘤平均有 4.44 个特征(范围为 3-6)。40个MIS黑色素瘤中有16个(40%)和16个浸润性黑色素瘤中有3个(18.8%)具有3个或更少的皮肤镜特征。这些结果与在两组ATN中观察到的结果相当。最常见的皮肤镜特征是色素网缺失或减少、回归结构和颗粒度。这些特征的结合最有助于确定需要进行基因组检测的病变:结论:仅凭临床和皮肤镜特征无法区分 MIS 和 ATN。无创基因组检测有助于区分低风险和高风险病变,并有助于临床管理决策。基因组检测对有大量皮损的患者尤其有帮助,根据临床和皮肤镜检查,有几个皮损被考虑进行活检。J Drugs Dermatol.2024;23(9):717-723. doi:10.36849/JDD.8454.
{"title":"Genomic Analysis Aids in the Management of Dermoscopically Atypical Pigmented Lesions.","authors":"Gary L Peck, Samantha R Johnson, Sarah W Matthews, Burkhard Jansen, Loren E Clarke, Rachel A Reifer, Maral Kibarian Skelsey","doi":"10.36849/JDD.8454","DOIUrl":"https://doi.org/10.36849/JDD.8454","url":null,"abstract":"<p><strong>Background: </strong>Numerous melanoma-specific dermoscopic features have been described in invasive melanomas, while fewer features are found in melanoma in situ (MIS) and atypical nevi (ATN). Consensus regarding which features are critical for the differentiation of MIS from ATN has not been reached.</p><p><strong>Purpose: </strong>Determine 1) whether there are dermoscopic features that differentiate early MIS from ATN, and 2) whether non-invasive assessment of genomic biomarkers (LINC00518 and PRAME) can aid in patient management.</p><p><strong>Methods: </strong>From 2018 to 2023, 56 melanomas were evaluated for 5 clinical and 13 dermoscopic features and melanoma-associated genomic biomarkers. Two groups of ATN with positive and negative genomic biomarkers were randomly selected for comparison.</p><p><strong>Results: </strong>All melanomas in this study expressed one or both melanoma-associated genomic markers. MIS had an average of 3.90 (range, 2-7) of the 13 dermoscopic features, while invasive melanomas had an average of 4.44 (range, 3-6). Sixteen of 40 (40%) MIS and 3 of 16 (18.8%) invasive melanomas had 3 or fewer dermoscopic features. These findings were comparable to those observed in both ATN groups. The most common dermoscopic features were absent or diminished pigment network, regression structures, and granularity. This combination of features was most helpful in identifying lesions for genomic testing.</p><p><strong>Conclusions: </strong>Clinical and dermoscopic features alone could not differentiate MIS from ATN. Non-invasive genomic testing helped differentiate lower from higher-risk lesions and aid in clinical management decisions. Genomic testing was particularly helpful in patients with large numbers of lesions with several being considered for biopsy based on clinical and dermoscopic examination. J Drugs Dermatol. 2024;23(9):717-723. doi:10.36849/JDD.8454.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists. 使用 GLP-1 激动剂后向 FDA 报告的皮肤科不良事件的横断面分析。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-09-01
Bianca E Ituarte, Mitchell A Taylor, Sierra I Thomas, Divya Sharma, Robin High, Ashley Wysong, Erin X Wei
{"title":"Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists.","authors":"Bianca E Ituarte, Mitchell A Taylor, Sierra I Thomas, Divya Sharma, Robin High, Ashley Wysong, Erin X Wei","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study. 古舍库单抗对中重度斑块状银屑病的实际疗效和安全性:一项为期 104 周的回顾性单中心研究。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-08-01 DOI: 10.36849/JDD.7486
Luigi Gargiulo, Luciano Ibba, Andrea Cortese, Francesco Toso, Carlo A Vignoli, Giovanni Fiorillo, Francesco Piscazzi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

Background: Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-world setting are still limited.

Materials and methods: We conducted a 104-week monocentric retrospective study on 102 psoriasis patients, all treated with guselkumab for at least 16 weeks. At each visit, we used the Psoriasis Area and Severity Index (PASI): effectiveness endpoints were the percentages of patients achieving 75%/90%/100% (PASI 75/90/100) improvement in PASI compared with baseline. The Kaplan-Meier curve was used to assess the drug survival.

Results: At week 16, PASI 90 and PASI 100 were achieved by 49.02% and 32.35% of patients. At week 52, PASI 90 and PASI 100 were achieved by 71.58% and 55.79% of patients. After 2 years, PASI 90 and PASI 100 were achieved by 79.63% and 61.11% of patients. Obese and overweight patients had comparable PASI 90 and PASI 100 responses throughout the study. At week 104, no significant differences were observed between bio-naïve and bio-experienced patients regarding all effectiveness endpoints. No significant safety signals were reported in our study. After 24 months, 91.57% of our cohort was still on treatment with guselkumab.

Conclusion: Our findings, although limited by the study's retrospective nature, confirm that guselkumab is a safe and effective therapeutic option for a "real-life" cohort of patients with psoriasis. J Drugs Dermatol. 2024;23(8):632-639.  doi:10.36849/JDD.7486R1.

背景介绍古舍库单抗是一种单克隆抗体,已被批准用于治疗中重度斑块状银屑病。有关古舍库单抗在现实世界中的有效性和安全性的长期数据仍然有限:我们对 102 名银屑病患者进行了为期 104 周的单中心回顾性研究,所有患者均接受了至少 16 周的古舍库单抗治疗。在每次就诊时,我们都使用了银屑病面积和严重程度指数(PASI):疗效终点是与基线相比,PASI 改善达到 75%/90%/100% (PASI 75/90/100)的患者百分比。采用 Kaplan-Meier 曲线评估药物存活率:第 16 周时,分别有 49.02% 和 32.35% 的患者达到了 PASI 90 和 PASI 100。第 52 周时,分别有 71.58% 和 55.79% 的患者达到了 PASI 90 和 PASI 100。两年后,分别有 79.63% 和 61.11% 的患者达到了 PASI 90 和 PASI 100。在整个研究过程中,肥胖和超重患者的 PASI 90 和 PASI 100 反应相当。在第104周时,在所有疗效终点方面,未观察到有生物治疗经验的患者与有生物治疗经验的患者之间存在明显差异。在我们的研究中,没有发现明显的安全性信号。24个月后,91.57%的患者仍在接受古舍库单抗治疗:结论:我们的研究结果虽然受限于研究的回顾性,但证实了古舍库单抗对于 "现实生活中 "的银屑病患者群体来说是一种安全有效的治疗选择。J Drugs Dermatol.2024;23(8):632-639.  doi:10.36849/JDD.7486R1.
{"title":"Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study.","authors":"Luigi Gargiulo, Luciano Ibba, Andrea Cortese, Francesco Toso, Carlo A Vignoli, Giovanni Fiorillo, Francesco Piscazzi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi","doi":"10.36849/JDD.7486","DOIUrl":"https://doi.org/10.36849/JDD.7486","url":null,"abstract":"<p><strong>Background: </strong>Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-world setting are still limited.</p><p><strong>Materials and methods: </strong>We conducted a 104-week monocentric retrospective study on 102 psoriasis patients, all treated with guselkumab for at least 16 weeks. At each visit, we used the Psoriasis Area and Severity Index (PASI): effectiveness endpoints were the percentages of patients achieving 75%/90%/100% (PASI 75/90/100) improvement in PASI compared with baseline. The Kaplan-Meier curve was used to assess the drug survival.</p><p><strong>Results: </strong>At week 16, PASI 90 and PASI 100 were achieved by 49.02% and 32.35% of patients. At week 52, PASI 90 and PASI 100 were achieved by 71.58% and 55.79% of patients. After 2 years, PASI 90 and PASI 100 were achieved by 79.63% and 61.11% of patients. Obese and overweight patients had comparable PASI 90 and PASI 100 responses throughout the study. At week 104, no significant differences were observed between bio-na&iuml;ve and bio-experienced patients regarding all effectiveness endpoints. No significant safety signals were reported in our study. After 24 months, 91.57% of our cohort was still on treatment with guselkumab.</p><p><strong>Conclusion: </strong>Our findings, although limited by the study's retrospective nature, confirm that guselkumab is a safe and effective therapeutic option for a \"real-life\" cohort of patients with psoriasis. J Drugs Dermatol. 2024;23(8):632-639.&nbsp; doi:10.36849/JDD.7486R1.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Characteristics Influencing Patient Selection of Sunscreen Between Urban and Rural Regions in the United States. 美国城市和农村地区影响患者选择防晒霜的特征比较。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-08-01 DOI: 10.36849/JDD.8449
Joshua Burshtein, Danny Zakria, Milaan Shah, Alexa Israeli, Chase Merritt, Dawn Merritt, Darrell Rigel

Sunscreen greatly reduces the risk of skin cancer and is recommended as a critical component of sun protection. There is limited literature on patient preferences for sunscreen characteristics. A cross-sectional survey was administered to patients in an urban city and rural area in the United States. Sun Protection Factor (SPF) was consistently the most important factor for patients when selecting sunscreen. However, numerous preferences for sunscreen characteristics vary between the 2 regions, including dermatologist recommendation, texture, ingredients, cost, broad-spectrum, and brand. Gaps in patient knowledge of sunscreen recommendations may be present and further educational programs may be necessary. J Drugs Dermatol. 2024;23(8):e171-e172. doi:10.36849/JDD.8449.

防晒霜可大大降低罹患皮肤癌的风险,被推荐为防晒的重要组成部分。有关患者对防晒霜特性偏好的文献资料十分有限。我们对美国城市和农村地区的患者进行了一项横断面调查。防晒系数 (SPF) 始终是患者在选择防晒霜时最看重的因素。然而,两个地区的患者对防晒霜特性的偏好各不相同,包括皮肤科医生的推荐、质地、成分、成本、广谱性和品牌。患者对防晒霜建议的了解可能存在差距,因此有必要开展进一步的教育计划。J Drugs Dermatol.2024;23(8):e171-e172. doi:10.36849/JDD.8449.
{"title":"Comparison of Characteristics Influencing Patient Selection of Sunscreen Between Urban and Rural Regions in the United States.","authors":"Joshua Burshtein, Danny Zakria, Milaan Shah, Alexa Israeli, Chase Merritt, Dawn Merritt, Darrell Rigel","doi":"10.36849/JDD.8449","DOIUrl":"10.36849/JDD.8449","url":null,"abstract":"<p><p>Sunscreen greatly reduces the risk of skin cancer and is recommended as a critical component of sun protection. There is limited literature on patient preferences for sunscreen characteristics. A cross-sectional survey was administered to patients in an urban city and rural area in the United States. Sun Protection Factor (SPF) was consistently the most important factor for patients when selecting sunscreen. However, numerous preferences for sunscreen characteristics vary between the 2 regions, including dermatologist recommendation, texture, ingredients, cost, broad-spectrum, and brand. Gaps in patient knowledge of sunscreen recommendations may be present and further educational programs may be necessary. J Drugs Dermatol. 2024;23(8):e171-e172. doi:10.36849/JDD.8449.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Palmoplantar Pustulosis: Therapy Update 掌跖脓疱病:治疗更新。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-08-01 DOI: 10.36849/JDD.7612
Shivali Devjani, Brandon Smith, Sogol Stephanie Javadi, Priya V Engel, George Han, Jashin J Wu

Palmoplantar pustulosis is a variant of psoriasis and a chronic skin disorder in which pruritic pustular eruptions appear on the palms and soles. It is thought to arise from a variety of genetic and environmental factors, is limited in prevalence, and has proven quite difficult to treat. The symptoms it inflicts on those affected are quite debilitating and the treatment landscape is constantly evolving, thus emphasizing the need for updates of the literature as time passes. Current treatments include topical agents, oral therapies, and phototherapy, amongst other treatments. In this systemic review, we explore newer literature from 2015 to 2022 on various treatment regimens for palmoplantar pustulosis. J Drugs Dermatol. 2024;23(8):626-631.     doi:10.36849/JDD.doi:10.36849/7612R1.

掌跖脓疱病是银屑病的一种变异型,也是一种慢性皮肤病,患者的手掌和足底会出现瘙痒性脓疱疹。它被认为是由多种遗传和环境因素引起的,发病率有限,而且治疗起来相当困难。该病给患者带来的症状会使人非常虚弱,而且治疗方法也在不断变化,因此随着时间的推移,需要对文献进行更新。目前的治疗方法包括局部用药、口服疗法和光疗等。在这篇系统性综述中,我们将探讨从 2015 年到 2022 年有关掌跖脓疱病各种治疗方案的最新文献。J Drugs Dermatol.2024;23(8):626-631.     doi:10.36849/JDD.doi:10.36849/7612R1.
{"title":"Palmoplantar Pustulosis: Therapy Update","authors":"Shivali Devjani, Brandon Smith, Sogol Stephanie Javadi, Priya V Engel, George Han, Jashin J Wu","doi":"10.36849/JDD.7612","DOIUrl":"10.36849/JDD.7612","url":null,"abstract":"<p><p>Palmoplantar pustulosis is a variant of psoriasis and a chronic skin disorder in which pruritic pustular eruptions appear on the palms and soles. It is thought to arise from a variety of genetic and environmental factors, is limited in prevalence, and has proven quite difficult to treat. The symptoms it inflicts on those affected are quite debilitating and the treatment landscape is constantly evolving, thus emphasizing the need for updates of the literature as time passes. Current treatments include topical agents, oral therapies, and phototherapy, amongst other treatments. In this systemic review, we explore newer literature from 2015 to 2022 on various treatment regimens for palmoplantar pustulosis. J Drugs Dermatol. 2024;23(8):626-631.&nbsp; &nbsp;&nbsp; doi:10.36849/JDD.doi:10.36849/7612R1.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas. Ixekizumab治疗涉及棘手身体部位的银屑病患者五年的疗效。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-08-01 DOI: 10.36849/JDD.8160
Alice B Gottlieb, April Armstrong, Andrew Blauvelt, Christopher E M Griffiths, Andreas Pinter, Melinda Gooderham, Mark Lomaga, Russel T Burge, Bruce W Konicek, Meghan Feely McDonald, Kyoungah See, Missy McKean-Matthews, Tomotaka Mabuchi

Background: Psoriasis involving challenging body areas, such as the scalp, face, palmoplantar surfaces, or nails, can be challenging to treat and negatively affects patient outcomes.

Objective: To assess clear responses and cumulative clinical benefits over 5 years of ixekizumab treatment of moderate-to-severe plaque psoriasis in patients with and without baseline involvement of challenging body areas.

Methods: This post hoc analysis included patients treated with ixekizumab in the UNCOVER-3 trial. We assessed PASI100 responses through the week (W) 264 and cumulative clinical benefits at W264 (calculated as least-squares mean of the percentage of maximum area under the curve for PASI100 and PASI% improvement and expressed as cumulative clearance days). Statistical differences were calculated via ANCOVA.

Results: A total of 385 patients were analyzed: 349 with scalp involvement, 152 with facial involvement, 96 with palmoplantar involvement, and 229 with nail involvement. Proportions of patients achieving PASI100 were numerically similar between patients with and without scalp and nail involvement. More patients without facial and palmoplantar involvement achieved PASI100 at W60 (only palmoplantar), W108, W156, W204, and W264 (only palmoplantar). At W264, cumulative clinical benefits for PASI100 and PASI% improvement were high and similar in both patient groups, with and without challenging body areas. A significant difference (P=0.006) was only observed for PASI% improvement between patients with and without nail involvement.

Conclusion: For most efficacy measures, patients treated with ixekizumab over 5 years achieved similar clear responses and cumulative clinical benefits regardless of baseline involvement of challenging body areas. J Drugs Dermatol. 2024;23(8):619-625.  doi:10.36849/JDD.8160.

背景:涉及头皮、面部、掌跖表面或指甲等具有挑战性的身体部位的银屑病可能具有治疗难度,并对患者的治疗效果产生负面影响:目的:评估ixekizumab治疗中度至重度斑块状银屑病患者5年的明显反应和累积临床疗效:这项事后分析包括UNCOVER-3试验中接受ixekizumab治疗的患者。我们评估了第 264 周的 PASI100 反应和第 264 周的累积临床疗效(以 PASI100 和 PASI% 改善曲线下最大面积百分比的最小二乘平均值计算,并以累积清除天数表示)。统计差异通过方差分析计算:共分析了 385 例患者:349 例头皮受累,152 例面部受累,96 例掌跖受累,229 例指甲受累。头皮和指甲受累与未受累的患者达到 PASI100 的比例在数量上相似。更多没有面部和掌跖受累的患者在 W60(仅掌跖)、W108、W156、W204 和 W264(仅掌跖)时达到了 PASI100。在 W264 期,两组患者的 PASI100 和 PASI% 改善累积临床疗效均较高,且相似,无论是否存在具有挑战性的身体部位。只有指甲受累和未受累的患者在 PASI% 改善方面存在明显差异(P=0.006):结论:就大多数疗效指标而言,无论基线受累的身体部位是否具有挑战性,使用伊昔单抗治疗 5 年的患者都能获得相似的明确反应和累积临床疗效。J Drugs Dermatol.2024;23(8):619-625.  doi:10.36849/JDD.8160.
{"title":"Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas.","authors":"Alice B Gottlieb, April Armstrong, Andrew Blauvelt, Christopher E M Griffiths, Andreas Pinter, Melinda Gooderham, Mark Lomaga, Russel T Burge, Bruce W Konicek, Meghan Feely McDonald, Kyoungah See, Missy McKean-Matthews, Tomotaka Mabuchi","doi":"10.36849/JDD.8160","DOIUrl":"https://doi.org/10.36849/JDD.8160","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis involving challenging body areas, such as the scalp, face, palmoplantar surfaces, or nails, can be challenging to treat and negatively affects patient outcomes.</p><p><strong>Objective: </strong>To assess clear responses and cumulative clinical benefits over 5 years of ixekizumab treatment of moderate-to-severe plaque psoriasis in patients with and without baseline involvement of challenging body areas.</p><p><strong>Methods: </strong>This post hoc analysis included patients treated with ixekizumab in the UNCOVER-3 trial. We assessed PASI100 responses through the week (W) 264 and cumulative clinical benefits at W264 (calculated as least-squares mean of the percentage of maximum area under the curve for PASI100 and PASI% improvement and expressed as cumulative clearance days). Statistical differences were calculated via ANCOVA.</p><p><strong>Results: </strong>A total of 385 patients were analyzed: 349 with scalp involvement, 152 with facial involvement, 96 with palmoplantar involvement, and 229 with nail involvement. Proportions of patients achieving PASI100 were numerically similar between patients with and without scalp and nail involvement. More patients without facial and palmoplantar involvement achieved PASI100 at W60 (only palmoplantar), W108, W156, W204, and W264 (only palmoplantar). At W264, cumulative clinical benefits for PASI100 and PASI% improvement were high and similar in both patient groups, with and without challenging body areas. A significant difference (P=0.006) was only observed for PASI% improvement between patients with and without nail involvement.</p><p><strong>Conclusion: </strong>For most efficacy measures, patients treated with ixekizumab over 5 years achieved similar clear responses and cumulative clinical benefits regardless of baseline involvement of challenging body areas. J Drugs Dermatol. 2024;23(8):619-625.&nbsp; doi:10.36849/JDD.8160.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Hidden Costs of Psoriasis: A Population-Based Study Evaluating How Psoriasis Severity Impacts Work Absenteeism. 银屑病的隐性成本:一项基于人群的研究,评估银屑病严重程度如何影响缺勤率。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-08-01 DOI: 10.36849/JDD.7550
Kathryn Lee, Paige Kingston, Margaret Y Huang, Danielle Yee, Hannah Peterson, Edwin Korouri, Rosario Agüero, April Armstrong

Background: Psoriasis patients experience physical and emotional burdens, which may lead to work-related productivity loss. This loss carries professional and financial repercussions. It is unknown whether the extent of psoriasis affects work absenteeism.

Objective: This study aims to compare work absenteeism between employed adults with mild versus moderate-to-severe psoriasis.

Methods: A national, cross-sectional study using the 2009 to 2019 Medical Expenditure Panel Survey evaluated 5,209,956 (weighted) adults aged ≥ 22 years. Work absenteeism was compared between adults with mild (4,521,687 weighted) and moderate-to-severe psoriasis (688,269 weighted).

Results: Work absenteeism, as measured by the average number of episodes per year that someone was absent from work for at least a half day, was significantly higher in patients with moderate-to-severe psoriasis than in patients with mild disease (4.4 episodes vs 2.8 episodes, P=0.002). Multivariable logistic regression models showed moderate-to-severe patients were 2.68 times more likely (95% CI:1.72-4.21; P<0.001) to take a half-day or more off from work than those with mild disease after adjusting for age, sex, race, ethnicity, poverty, cognitive limitations, insurance, education, and comorbidities.

Conclusion: Disease severity directly impacts work absenteeism in psoriasis patients. Early diagnosis and treatment with appropriate therapies are needed to reduce disease severity and limit economic loss and professional ramifications associated with psoriasis. J Drugs Dermatol. 2024;23(8):640-644.  doi:10.36849/JDD.7550.

背景:银屑病患者承受着身体和精神上的负担,这可能会导致与工作相关的生产力损失。这种损失会带来职业和经济影响。银屑病的严重程度是否会影响缺勤率,目前尚不清楚:本研究旨在比较患有轻度银屑病和中重度银屑病的成年人的缺勤情况:一项全国性横断面研究利用 2009 年至 2019 年医疗支出小组调查对 5,209,956 名(加权)22 岁的成年人进行了评估。对轻度银屑病患者(4521687 人加权)和中重度银屑病患者(688269 人加权)的缺勤情况进行了比较:中重度银屑病患者的旷工率明显高于轻度银屑病患者(4.4 次对 2.8 次,P=0.002),旷工率以每年平均旷工至少半天的次数来衡量。多变量逻辑回归模型显示,在调整年龄、性别、种族、民族、贫困、认知能力限制、保险、教育和合并症等因素后,中重度患者请假半天或半天以上的可能性是轻度患者的2.68倍(95% CI:1.72-4.21;P<0.001):结论:疾病严重程度直接影响银屑病患者的缺勤率。结论:疾病的严重程度直接影响银屑病患者的旷工率,因此需要早期诊断并采用适当的疗法进行治疗,以降低疾病的严重程度,减少与银屑病相关的经济损失和职业影响。J Drugs Dermatol.2024;23(8):640-644.  doi:10.36849/JDD.7550.
{"title":"The Hidden Costs of Psoriasis: A Population-Based Study Evaluating How Psoriasis Severity Impacts Work Absenteeism.","authors":"Kathryn Lee, Paige Kingston, Margaret Y Huang, Danielle Yee, Hannah Peterson, Edwin Korouri, Rosario Agüero, April Armstrong","doi":"10.36849/JDD.7550","DOIUrl":"https://doi.org/10.36849/JDD.7550","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis patients experience physical and emotional burdens, which may lead to work-related productivity loss. This loss carries professional and financial repercussions. It is unknown whether the extent of psoriasis affects work absenteeism.</p><p><strong>Objective: </strong>This study aims to compare work absenteeism between employed adults with mild versus moderate-to-severe psoriasis.</p><p><strong>Methods: </strong>A national, cross-sectional study using the 2009 to 2019 Medical Expenditure Panel Survey evaluated 5,209,956 (weighted) adults aged &ge; 22 years. Work absenteeism was compared between adults with mild (4,521,687 weighted) and moderate-to-severe psoriasis (688,269 weighted).</p><p><strong>Results: </strong>Work absenteeism, as measured by the average number of episodes per year that someone was absent from work for at least a half day, was significantly higher in patients with moderate-to-severe psoriasis than in patients with mild disease (4.4 episodes vs 2.8 episodes, P=0.002). Multivariable logistic regression models showed moderate-to-severe patients were 2.68 times more likely (95% CI:1.72-4.21; P&lt;0.001) to take a half-day or more off from work than those with mild disease after adjusting for age, sex, race, ethnicity, poverty, cognitive limitations, insurance, education, and comorbidities.</p><p><strong>Conclusion: </strong>Disease severity directly impacts work absenteeism in psoriasis patients. Early diagnosis and treatment with appropriate therapies are needed to reduce disease severity and limit economic loss and professional ramifications associated with psoriasis. J Drugs Dermatol. 2024;23(8):640-644.&nbsp; doi:10.36849/JDD.7550.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of At-Home Narrow-Band UVB Phototherapy for Mild-to-Severe Psoriasis: A Retrospective, Multicenter, Observational Study. 居家窄波段 UVB 光疗对轻度至重度银屑病的影响:一项回顾性多中心观察研究。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-08-01 DOI: 10.36849/JDD.7815
{"title":"The Impact of At-Home Narrow-Band UVB Phototherapy for Mild-to-Severe Psoriasis: A Retrospective, Multicenter, Observational Study.","authors":"","doi":"10.36849/JDD.7815","DOIUrl":"10.36849/JDD.7815","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Prospective, Multi-Center Study to Evaluate the Safety and Efficacy of a Vegan Nutraceutical to Improve Hair Growth and Quality in Females Following a Plant-Based Diet 一项前瞻性多中心研究,旨在评估素食营养保健品对改善植物性饮食女性头发生长和质量的安全性和有效性。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-08-01 DOI: 10.36849/JDD.8421
Raja K Sivamani, Glynis Ablon, Yvonne Nong, Jessica Maloh, Adina Hazan, Isabelle Raymond

Hair thinning affects upwards of 50% of women by age 50, impacting their social-emotional wellbeing. It is a condition now thought to be driven by a multi-factorial etiology, including diet and nutrition. Women following vegan, vegetarian, or other plant-based diets have specific needs for nutrients traditionally sourced from animals, which could affect hair health. To support hair growth and quality in women following a plant-based diet, a novel vegan nutraceutical (Nutrafol Women's Vegan Capsules, Nutraceutical Wellness, Inc., New York, NY) was evaluated for its ability to support hair health. The objectives of this 6-month, multi-site, single-blind prospective clinical study was to evaluate the safety and efficacy of the nutraceutical to improve hair growth and quality in women consuming a plant-based diet. The primary endpoint in this study was an increase in terminal hair count at day 180 compared with baseline, as assessed through phototrichogram analysis. Ninety-five subjects completed the study. Daily intake of the nutraceutical resulted in a significant increase in the number of terminal hairs at day 90 (P<0.01) and day 180 (P<0.01). There was also an increase in total hair counts (P<0.01), the terminal-to-vellus ratio (P<0.01), and a decrease in shedding (P<0.01). Global Investigator Ratings revealed improved hair growth (P<0.00001) and overall quality (P<0.00001). In-person hair strength and brittleness assessments significantly improved as well (P<0.01 for both). A significant proportion of subjects reported improved hair quality, appearance, texture, and volume. Hair problems affecting the quality of life of the subjects were also reported as improved. This study demonstrated significant improvements in hair growth and quality in a plant-based population with a vegan nutraceutical. ClinicalTrials.gov Identifier: NCT05332743. J Drugs Dermatol. 2024;23(8):661-668.  doi:10.36849/JDD.8421.

到 50 岁时,50% 以上的女性会受到头发稀疏的影响,从而影响她们的社会情感。目前认为,头发稀疏是由饮食和营养等多因素造成的。为了帮助采用植物性饮食的女性提高头发生长速度和质量,我们对一种新型素食营养保健品(Nutrafol Women's Vegan Capsules,Nutraceutical Wellness, Inc.这项为期 6 个月、多地点、单盲前瞻性临床研究的目的是评估该营养保健品在改善以植物为基础饮食的女性的头发生长和质量方面的安全性和有效性。这项研究的主要终点是通过光电图谱分析评估与基线相比,第 180 天的末端毛发数量是否增加。95名受试者完成了这项研究。 每天摄入营养保健品可使末端毛发数量在第90天(P<0.01)和第180天(P<0.01)显著增加。总毛发数(P<0.01)、顶端毛发与细长毛发的比率(P<0.01)也有所增加,脱落率(P<0.01)有所下降。全球调查员评分显示,头发生长(P<0.00001)和整体质量(P<0.00001)均有所改善。亲自进行的头发强度和脆性评估也有明显改善(P<0.01)。相当一部分受试者表示头发质量、外观、质地和发量均有所改善。影响受试者生活质量的头发问题也得到了改善。这项研究表明,纯素营养保健品对植物人群的头发生长和质量有明显改善。ClinicalTrials.gov Identifier:NCT05332743。J Drugs Dermatol.2024;23(8):661-668.  doi:10.36849/JDD.8421.
{"title":"A Prospective, Multi-Center Study to Evaluate the Safety and Efficacy of a Vegan Nutraceutical to Improve Hair Growth and Quality in Females Following a Plant-Based Diet","authors":"Raja K Sivamani, Glynis Ablon, Yvonne Nong, Jessica Maloh, Adina Hazan, Isabelle Raymond","doi":"10.36849/JDD.8421","DOIUrl":"10.36849/JDD.8421","url":null,"abstract":"<p><p>Hair thinning affects upwards of 50% of women by age 50, impacting their social-emotional wellbeing. It is a condition now thought to be driven by a multi-factorial etiology, including diet and nutrition. Women following vegan, vegetarian, or other plant-based diets have specific needs for nutrients traditionally sourced from animals, which could affect hair health.&nbsp;To support hair growth and quality in women following a plant-based diet, a novel vegan nutraceutical (Nutrafol Women's Vegan Capsules, Nutraceutical Wellness, Inc., New York, NY) was evaluated for its ability to support hair health. The objectives of this 6-month, multi-site, single-blind prospective clinical study was to evaluate the safety and efficacy of the nutraceutical to improve hair growth and quality in women consuming a plant-based diet. The primary endpoint in this study was an increase in terminal hair count at day 180 compared with baseline, as assessed through phototrichogram analysis. Ninety-five subjects completed the study.&nbsp;Daily intake of the nutraceutical resulted in a significant increase in the number of terminal hairs at day 90 (P&lt;0.01) and day 180 (P&lt;0.01). There was also an increase in total hair counts (P&lt;0.01), the terminal-to-vellus ratio (P&lt;0.01), and a decrease in shedding (P&lt;0.01). Global Investigator Ratings revealed improved hair growth (P&lt;0.00001) and overall quality (P&lt;0.00001). In-person hair strength and brittleness assessments significantly improved as well (P&lt;0.01 for both). A significant proportion of subjects reported improved hair quality, appearance, texture, and volume. Hair problems affecting the quality of life of the subjects were also reported as improved. This study demonstrated significant improvements in hair growth and quality in a plant-based population with a vegan nutraceutical. ClinicalTrials.gov Identifier: NCT05332743. J Drugs Dermatol. 2024;23(8):661-668.&nbsp; doi:10.36849/JDD.8421.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and Tolerance Evaluation of a Suncare Product in Ethnically Diverse Children With Atopic Dermatitis-Prone Skin 在患有特应性皮炎的不同种族儿童中进行防晒产品的安全性和耐受性评估。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-08-01 DOI: 10.36849/JDD.8282
Hawasatu Dumbuya, Zoe Diana Draelos, Caroline Le Floc'h, Katharine Podimatis

Atopic Dermatitis (AD) is a common chronic inflammatory skin condition, with high prevalence in children. Sun protection is important for children with eczema and AD-prone skin, yet many sunscreens can cause skin irritation due to their formulations. In this study, we evaluated the safety and tolerance of an SPF 50 sunscreen in ethnically diverse children with a history of AD over 4 weeks of product use. A total of 45 children from diverse racial/ethnic backgrounds, aged 3 to 12 years old with skin phototypes I-VI, plus a history of eczema and perceived sensitive skin completed the study. All participants applied sunscreen daily on the face and body, at least 15 minutes prior to sun exposure and as needed. After 4 weeks, evaluations were performed by a dermatologist and by participants for tolerability. Product performance questionnaires were also completed by parents/guardians of pediatric participants. After 4 weeks of sunscreen application, tolerability assessments of skin dryness, peeling, erythema, and edema were all absent in children participants. Parent/guardian evaluations of sunscreen tolerability for their child also revealed no perceived skin issues. These results were consistent with no adverse event being observed throughout the study. Parents/guardians reported that sunscreen application on children was smooth and even, with the absence of a white cast appearance on children with skin of color. We conclude from this study that this SPF 50 sunscreen is safe to use in ethnically diverse children with a history of AD and sensitive skin. J Drugs Dermatol. 2024;23(8):669-673.  doi:10.36849/JDD.8282.

特应性皮炎(AD)是一种常见的慢性炎症性皮肤病,在儿童中发病率很高。防晒对患有湿疹和易患特应性皮炎的儿童非常重要,但许多防晒霜由于其配方可能会对皮肤造成刺激。在这项研究中,我们评估了一种 SPF 50 防晒霜在不同种族、有 AD 病史的儿童中使用 4 周后的安全性和耐受性。共有 45 名来自不同种族/民族背景的 3 至 12 岁儿童完成了这项研究,他们的皮肤光型为 I-VI,并有湿疹和敏感性皮肤的病史。所有参与者每天都在晒太阳前至少 15 分钟或根据需要在面部和身体涂抹防晒霜。4 周后,由皮肤科医生和参与者对产品的耐受性进行评估。儿科参与者的父母/监护人也填写了产品性能问卷。涂抹防晒霜 4 周后,儿童参与者的皮肤干燥、脱皮、红斑和水肿等耐受性评估结果均为零。家长/监护人对其子女防晒霜耐受性的评估也显示,没有发现任何皮肤问题。这些结果与整个研究过程中未观察到不良事件是一致的。家长/监护人表示,儿童涂抹防晒霜的过程平滑、均匀,有色皮肤的儿童涂抹后不会出现白斑。我们从这项研究中得出结论,这款 SPF 50 防晒霜可安全用于有注意力缺失症病史和皮肤敏感的不同种族儿童。J Drugs Dermatol.2024;23(8):669-673.  doi:10.36849/JDD.8282.
{"title":"Safety and Tolerance Evaluation of a Suncare Product in Ethnically Diverse Children With Atopic Dermatitis-Prone Skin","authors":"Hawasatu Dumbuya, Zoe Diana Draelos, Caroline Le Floc'h, Katharine Podimatis","doi":"10.36849/JDD.8282","DOIUrl":"10.36849/JDD.8282","url":null,"abstract":"<p><p>Atopic Dermatitis (AD) is a common chronic inflammatory skin condition, with high prevalence in children. Sun protection is important for children with eczema and AD-prone skin, yet many sunscreens can cause skin irritation due to their formulations. In this study, we evaluated the safety and tolerance of an SPF 50 sunscreen in ethnically diverse children with a history of AD over 4 weeks of product use. A total of 45 children from diverse racial/ethnic backgrounds, aged 3 to 12 years old with skin phototypes I-VI, plus a history of eczema and perceived sensitive skin completed the study. All participants applied sunscreen daily on the face and body, at least 15 minutes prior to sun exposure and as needed. After 4 weeks, evaluations were performed by a dermatologist and by participants for tolerability. Product performance questionnaires were also completed by parents/guardians of pediatric participants. After 4 weeks of sunscreen application, tolerability assessments of skin dryness, peeling, erythema, and edema were all absent in children participants. Parent/guardian evaluations of sunscreen tolerability for their child also revealed no perceived skin issues. These results were consistent with no adverse event being observed throughout the study. Parents/guardians reported that sunscreen application on children was smooth and even, with the absence of a white cast appearance on children with skin of color. We conclude from this study that this SPF 50 sunscreen is safe to use in ethnically diverse children with a history of AD and sensitive skin. J Drugs Dermatol. 2024;23(8):669-673.&nbsp; doi:10.36849/JDD.8282.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Drugs in Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1